Revenue fell to $4.53 million from $5.64 million a year ago. The Street estimated $13.97 million, which may not be comparable.
The clinical-stage drugmaker said it has sufficient funds to operate through 2024.
|Insider Sell: Block|
|Insider Sell: Berkshire Hathaway|
|Insider Sell: Trupanion|
|Insider Buy: Ikena Oncology|
|Insider Sell: Apellis Pharmaceuticals|